UCB (OTCMKTS:UCBJF) Stock Rating Upgraded by ValuEngine

UCB (OTCMKTS:UCBJF) was upgraded by equities researchers at ValuEngine from a “sell” rating to a “hold” rating in a research report issued on Wednesday, ValuEngine reports.

OTCMKTS:UCBJF remained flat at $$68.95 during mid-day trading on Wednesday. The company has a 50 day simple moving average of $73.66 and a 200-day simple moving average of $79.72. UCB has a 1 year low of $68.95 and a 1 year high of $88.67.

UCB Company Profile

UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.

Read More: What causes a stock to be most active?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.